Thus, metabolic modification and differential regulation of CD4+ versus CD8+ T cell responses in Fli1 deficiency may be beneficial for maintaining GVL activity, while attenuating GVHD pathogenicity. The gene discussed is FLI1; the disease is graft versus host disease.